Nancy A. Melville A high proportion of patients treated with the thyroid eye disease drug teprotumumab (Tepezza) report signs of hearing dysfunction after three to four infusions, with nearly half having symptoms that appear persistent, according to a single-center analysis. “Hearing loss is a concerning adverse event [of teprotumumab] and its mechanism, and reversibility should...